

Changes to comparators for November 2016

The following additions, deletions and changes have been made to the comparators for November 2016 dashboard.

Data has been refreshed for all comparators apart from Emergency Diabetes Admissions, Emergency Asthma Admissions and Emergency COPD Admissions.

Withdrawn Comparators	Comments
CVD/CHD: Atrial fibrillation (AF004) % achieving upper threshold or above (CCG)	No longer exists within QOF for 15/16. Replaced by Atrial fibrillation (AF007) % achieving upper threshold or above
CVD/CHD: Atrial fibrillation (AF004) % underlying achievement (CCG)	No longer exists within QOF for 15/16 Replaced by Atrial fibrillation (AF007) % underlying achievement
CVD/CHD: Atrial fibrillation Access to audit tool (CCG)	This comparator that was included in earlier versions of the MO Dashboard has been removed from this version. We are urgently exploring the development of a generic comparator to enable organisations to benchmark the use of patient safety audit software in line with the NICE guideline on Medicines Optimisation.
Diabetes: Antidiabetic drugs (BNF section 6.1.2) (CCG)	This is a very important topic and further work is required to explore the most appropriate data and effective method to represent a comparator in this area. The existing antidiabetic data has been removed while this work continues.
Patient Safety: Safety Audit Software (CCG)	The comparator on patient safety audit software that was included in earlier versions of the MO Dashboard has been removed from this version. We are urgently exploring the development of a generic comparator to enable organisations to benchmark the use of patient safety audit software in line with the NICE guideline on Medicines Optimisation.
Osteoporosis: DDD Osteoporosis drugs per 10,000 resident population age 50 and over (CCG)	The latest release of the Innovation Scorecard no longer contains osteoporosis data resulting in data not been included in the Medicines Optimisation Dashboard.

Additional Comparators	Comments
CVD/CHD: Atrial fibrillation (AF007) % achieving upper threshold or above (CCG)	Replaces Atrial fibrillation (AF004) % achieving upper threshold or above
CVD/CHD: Atrial fibrillation (AF007) % underlying achievement (CCG)	Replaces Atrial fibrillation (AF004) % underlying achievement
Patient Experience: Awareness of the on-line ordering of repeat prescriptions service (CCG)	Evaluation undertaken by Monmouth Partners with a recommendation from the evaluation being "Patient experience data for medicines is being collated nationally and should be included in the current MO Dashboard for NHS stakeholders. ' <i>Understanding the patient experience</i> ' is the first principle of medicines optimisation and this should be echoed through future reiterations of the MO Dashboard'.
Patient Experience: Use of the on-line ordering of repeat prescriptions service (CCG)	Evaluation undertaken by Monmouth Partners with a recommendation from the evaluation being "Patient experience data for medicines is being collated nationally and should be included in the current MO Dashboard for NHS stakeholders. ' <i>Understanding the patient experience</i> ' is the first principle of medicines optimisation and this should be echoed through future reiterations of the MO Dashboard'.
Patient Experience: CQC In-patient Survey (2015) Q60 to Q63 (Trust)	Evaluation undertaken by Monmouth Partners with a recommendation from the evaluation being "Patient experience data for medicines is being collated nationally and should be included in the current MO Dashboard for NHS stakeholders. ' <i>Understanding the patient experience</i> ' is the first principle of medicines optimisation and this should be echoed through future reiterations of the MO Dashboard'.

Changes to Comparators	Comments
Antibiotics: Antibacterial items per STAR-PU (CCG)	Data is now represented as 12 months accumulated to align to other initiatives such as the Quality Premium. This also takes into account any seasonal variation.
Antibiotics: Co-amoxiclav, Cephalosporins and Quinolones % items (CCG)	Data is now represented as 12 months accumulated to align to other initiatives such as the Quality Premium. This also takes into account any seasonal variation.
CVD/CHD: Oral Anticoagulants % items (CCG)	The stacked bar chart has now been changed to a simple bar chart with the comparator changed to: Number of prescription items for apixaban, dabigatran etexilate, edoxaban and rivaroxaban as a percentage of the total number of prescription items for apixaban, dabigatran etexilate, edoxaban, rivaroxaban and warfarin sodium. This allows simple monitoring over time and can be displayed clearly on the time series chart.
Biosimilar: % of Infliximab biosimilars (Trust)	The stacked bar chart has now been changed to a simple bar chart with the comparator changed to: The percentage of the biosimilar versions for Infliximab purchased by volume. This allows simple monitoring over time and can be displayed clearly on the time series chart.